Viosera Therapeutics Competitors and Similar CompaniesClear all
Viosera Therapeutics's competitors and similar companies include Allucent TX, Tetherex, Medivir and Lava Therapeutics.
 Viosera Therapeutics Viosera Therapeutics is a company developing combination therapies for infections and cancer. |  Allucent TX Allucent (also known as Pharm-Olam) is a contract research organization offering clinical research services (Phase I-IV) to the pharmaceutical, biotechnology, and medical device industries. |  Tetherex Tetherex Pharmaceuticals Corp is a biopharmaceutical company focused on development of therapeutics for the treatment of inflammation, thrombosis and tumor metastasis across a broad range of severe diseases. |  Medivir Medivir is a company that researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. |  Lava Therapeutics Lava Therapeutics is a biotech company that develops T-cell engagers for the therapy of solid tumors and hematologic malignancies. | |
Founding Date | Founding Date 2016 | Founding Date 1994 | Founding Date 2014 | Founding Date 1988 | Founding Date 2016 |
Type | Type Private | Type Subsidiary | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Overland, US HQ | Locations Chicago, US HQ Scherpenheuvel Zichem, BE Sao Paulo, BR Montréal, CA Zagreb, HR Prague, CZ Paris, FR see more | Locations Oklahoma City, US HQ Morrisville, US | Locations Huddinge, SE HQ | Locations Utrecht, NL HQ Philadelphia, US |
Employees | Employees 1 | Employees 4831% decrease | Employees N/A | Employees 9 | Employees 34 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 39.2 m | Valuation ($) 53.4 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) kr8.5m (FY, 2025) | Revenue (est.) $12m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit kr8.5m (FY, 2025) | Gross profit $12m (FY, 2024) |
Net income | Net income N/A | Net income N/A | Net income N/A | Net income (kr94.4m) (FY, 2025) | Net income ($25.1m) (FY, 2024) |
Funding | |||||
Latest funding round | Latest funding round $ 150k (about 7 years ago) | Latest funding round N/A | Latest funding round $ 43m (about 8 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 150k | Total funding raised N/A | Total funding raised $ 46.2m | Total funding raised N/A | Total funding raised $ 102.8m |
For sources of this data, please see the company profile
View Company Profiles
Allucent TX
HQ
Chicago, US
Allucent (also known as Pharm-Olam) is a contract research organization offering clinical research services (Phase I-IV) to the pharmaceutical, biotechnology, and medical device industries.
View companyTetherex
HQ
Oklahoma City, US
Tetherex Pharmaceuticals Corp is a biopharmaceutical company focused on development of therapeutics for the treatment of inflammation, thrombosis and tumor metastasis across a broad range of severe diseases.
View companyMedivir
HQ
Huddinge, SE
Employees
9
Medivir is a company that researches, develops, and sells pharmaceuticals primarily for the treatment of oncology.
View companyLava Therapeutics
HQ
Utrecht, NL
Employees
34
Lava Therapeutics is a biotech company that develops T-cell engagers for the therapy of solid tumors and hematologic malignancies.
View company